Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
|Articles|September 9, 2021
Pharmacy Clinical Pearl of the Day: Pneumonia Vaccines
Author(s)Saro Arakelians, PharmD
Vaccines help prevent pneumococcal disease, which is any type of illness caused by Streptococcus pneumoniae bacteria.
Advertisement
Clinical Pearl of the Day: Pneumonia vaccines
- Vaccines help prevent
pneumococcal disease , which is any type of illness caused by Streptococcus pneumoniae bacteria.
Explanation:
- Types of pneumonia vaccines approved by the FDA:
- Pneumococcal conjugate vaccine or PCV13.
- Pneumococcal polysaccharide vaccine or PPSV23.
- Pneumococcal 20-valent Conjugate Vaccine or Prevnar 20.
- CDC recommends PCV13:
- For all children younger than 2 years of age and people 2 years of age and older with certain conditions.
- CDC recommends PRSV23:
- For all adults 65 years of age or older, people 2 through 64 years of age with certain medical conditions.
- For all adults 19 through 64 years of age who smoke cigarettes.
- Prevnar 20 is recommended for adults 18 years of age and older.
Reference:
Advertisement
Related to this article
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5